| Literature DB >> 31042466 |
Min Ni1, Ashley Solmonson2, Chunxiao Pan2, Chendong Yang2, Dan Li2, Ashley Notzon2, Ling Cai3, Gerardo Guevara2, Lauren G Zacharias2, Brandon Faubert2, Hieu S Vu2, Lei Jiang4, Bookyung Ko2, Noriko Merida Morales2, Jimin Pei5, Gonçalo Vale6, Dinesh Rakheja7, Nick V Grishin8, Jeffrey G McDonald6, Garrett K Gotway9, Markey C McNutt9, Juan M Pascual10, Ralph J DeBerardinis11.
Abstract
Inborn errors of metabolism (IEMs) link metabolic defects to human phenotypes. Modern genomics has accelerated IEM discovery, but assessing the impact of genomic variants is still challenging. Here, we integrate genomics and metabolomics to identify a cause of lactic acidosis and epilepsy. The proband is a compound heterozygote for variants in LIPT1, which encodes the lipoyltransferase required for 2-ketoacid dehydrogenase (2KDH) function. Metabolomics reveals abnormalities in lipids, amino acids, and 2-hydroxyglutarate consistent with loss of multiple 2KDHs. Homozygous knockin of a LIPT1 mutation reduces 2KDH lipoylation in utero and results in embryonic demise. In patient fibroblasts, defective 2KDH lipoylation and function are corrected by wild-type, but not mutant, LIPT1 alleles. Isotope tracing reveals that LIPT1 supports lipogenesis and balances oxidative and reductive glutamine metabolism. Altogether, the data extend the role of LIPT1 in metabolic regulation and demonstrate how integrating genomics and metabolomics can uncover broader aspects of IEM pathophysiology.Entities:
Keywords: 2-ketoacid dehydrogenase; epilepsy,developmental delay; fatty acid oxidation; genomics; inborn errors of metabolism; lactic acidosis; lipogenesis; lipoylation; metabolomics
Mesh:
Substances:
Year: 2019 PMID: 31042466 DOI: 10.1016/j.celrep.2019.04.005
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423